@qunz:$Grab Holdings(GRAB)$Not sure why the drop when business is bomming more than ever.With GxS bank launched, cash flow will be even smoother. Have big hopes for Grab, kinda reminds me of Tesla when it was trading at 2 bucks, everyone was saying its unviable and going bankrupt.

@EdwardHughes:Novavax stunned the market with a Q2 earnings release that underperformed significantly. It also markedly downgraded its FY22 revenue guidance, given waning demand and oversupply of COVID vaccines.However, we believe the de-risking in its revenue guidance for Novavax is constructive, lowering the market's expectations. Therefore, we are confident that it should help Novavax outperform in H2'22.The steep sell-off forced NVAX close to its June lows, which was held resiliently. With the recovery in market sentiments for biotech stocks, we are confident its lows should hold.Therefore, we revise our rating from Sell to Speculative Buy, with a price target of $60.

@JunioR:$Vanguard Total International Stock Index Fund ETF Shares(VXUS)$is an etf that consists of all the international stocks, similar to VTI or IWDA, but excludes the US stock market. This makes it a suitable etf for those who are looking to diversify their stock holdings globally while also trying to avoid the US stocks. There could be a few reasons for this. First, the investor could be wary of US stock market valuations. At a current P/E ratio of 20, the US stock market is still way higher than the long term average P/E ratio of 15-16. And this is after the near 20% correction of recent weeks. This could imply that the US market could potentially continue to fall, and that the recent surge could just be a dead cat bounce. Another reas